Publicacións (202) Publicacións de CELIA OREJA GUEVARA

2024

  1. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

    Neurologia, Vol. 39, Núm. 2, pp. 196-208

  2. Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 84

  3. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

  4. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

    Frontiers in Neurology, Vol. 15

2023

  1. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 15-21

  2. Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel

    Neurology and Therapy, Vol. 12, Núm. 2, pp. 427-439

  3. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

    Digital Health, Vol. 9

  4. Diagnosis and treatment of progressive multiple sclerosis: A position paper

    European Journal of Neurology, Vol. 30, Núm. 1, pp. 9-21

  5. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

    Multiple Sclerosis Journal

  6. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  7. European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

    European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176

  8. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 5-13

  9. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

    Multiple Sclerosis and Related Disorders, Vol. 69

  10. Monitoring response to disease-modifying treatment in multiple sclerosis

    Neurology Perspectives, Vol. 3, Núm. 2

  11. Predictors of treatment switching in the Big Multiple Sclerosis Data Network

    Frontiers in Neurology, Vol. 14

  12. Ravulizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

    Annals of Neurology, Vol. 93, Núm. 6, pp. 1053-1068

  13. Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study

    Multiple Sclerosis and Related Disorders, Vol. 69

  14. Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies

    Neurology(R) neuroimmunology & neuroinflammation, Vol. 10, Núm. 1

  15. Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care

    Advances in Therapy, Vol. 40, Núm. 12, pp. 5131-5136

  16. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644